Cartalax + BPC-157 + Thymosin beta-4 research monograph — a three-part repair blend (components studied separately; the blend is not)

This product is a fixed-ratio blend of three research compounds, each of which has its own VialTalk monograph: Cartalax, BPC-157, and Thymosin beta-4. It is marketed for connective-tissue and soft-tissue repair research and is commonly labelled by total peptide load (e.g., "Cartalax / TB4 / BPC-157 — 40 mg"). The research interest in combining them is that each approaches repair through a different mechanism — a Khavinson connective-tissue bioregulator (Cartalax), a broad cytoprotective/angiogenic repair peptide (BPC-157), and an actin-regulating cell-migration protein (Thymosin beta-4) — so the blend is discussed as a convergence of complementary repair pathways rather than as a single new molecule. This monograph summarises the components' roles, the rationale for combining them, and why a blend is harder to study and to dose than any single compound.

Chemical identity and structure.
The blend contains three distinct entities at a fixed ratio set by the manufacturer; there is no single molecular weight or formula, and each component keeps its own identity and pharmacokinetics. Cartalax is a vendor-branded Khavinson-family short peptide marketed for cartilage/connective-tissue research — a short peptide of roughly 400–500 g/mol — but its amino-acid sequence is not unambiguously published under the "Cartalax" brand name in peer-reviewed literature, so the COA's stated sequence, not the brand name, is the controlling identity. BPC-157 is a synthetic 15-amino-acid "stable gastric pentadecapeptide" (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), a partial fragment of a protein identified in human gastric juice. Thymosin beta-4 here denotes the full endogenous 43-amino-acid actin-regulating protein (TB4) — distinct from the shorter synthetic "TB-500" fragment sold separately; because vendors use the two names interchangeably, which one a given vial contains should be confirmed on the COA. See the individual VialTalk monographs for per-compound chemistry.

Mechanism of action.
The three components act through different mechanisms that share a repair theme but do not converge on a single pathway. Cartalax sits in the Khavinson "short-peptide bioregulator" framework, whose hypothesis is that ultrashort peptides modulate tissue-specific gene expression (for Cartalax, connective-tissue/chondrocyte-associated) — a regulatory model that remains theoretical relative to receptor pharmacology and is supported mainly by the originating research network. BPC-157 is studied for angiogenesis (reported via the VEGFR2 pathway), nitric-oxide-system modulation, and cytoprotection, with accelerated repair reported in tendon, muscle, and gastrointestinal injury models; no single unifying mechanism has been established. Thymosin beta-4 sequesters G-actin, promoting cell migration, supporting angiogenesis, and reducing fibrosis — processes central to wound healing. The rationale for the blend is that these cover different facets of tissue repair at once; it is an inferred combination rationale, not a demonstrated synergy.

Research applications and the evidence base.
The evidence base for this product is per-component, not combination-level, and its strength is uneven across the three. Thymosin beta-4 has the broadest base, including preclinical repair models and some human clinical research (for example, formulations studied for ophthalmic and dermal wound applications). BPC-157 has an extensive but almost entirely preclinical (largely rodent) injury-and-recovery literature, with no single established mechanism and no completed Western Phase III human trials. Cartalax has the thinnest and least-independent base: sparse research concentrated within the Khavinson tradition, much of it in Russian-language journals, and — as noted above — without an unambiguous published sequence under the brand name. Critically, there are no dedicated controlled trials of this three-compound blend as a fixed formulation; the case for the combination rests on the components' separate mechanisms and on the general logic of covering multiple repair pathways at once. None of the three components is approved for human therapeutic use in any major Western jurisdiction. That per-component, largely-preclinical framing should be kept explicit when reading any "repair blend" claim.

Community protocol information.
Blends are sold at a fixed total milligram load split across the three components in a set ratio (this product is commonly labelled around a 40 mg total), reconstituted with bacteriostatic water and administered subcutaneously; community protocols dose by total blend volume and extrapolate ranges from the individual components' protocols. Blend note: blend dosing is markedly more variable and far less studied than single-compound dosing. A fixed ratio means the three components cannot be titrated independently — raising the dose for one raises it for all — and there are no controlled pharmacokinetic or interaction data for this specific combination. Any blend dose figure should be treated as community practice extrapolated from single-compound protocols, not a validated protocol, and read alongside the three individual monographs.

Stack combinations researchers commonly use.
This product is itself a stack — a connective-tissue bioregulator combined with two soft-tissue repair peptides. In community practice it is discussed in recovery/regeneration framing and sometimes alongside other repair peptides (such as KPV or GHK-Cu) or GH secretagogues; none of those extended combinations has controlled combination evidence, and the rationale remains preliminary at every level.

Storage and handling.
Store the lyophilized blend frozen (−20 °C); after reconstitution, refrigerate at 2–8 °C and use within roughly two to four weeks, avoiding freeze–thaw. A practical note for blends: the formulation is only as stable as its least-stable component, so default to the most conservative storage window among the three peptides.

Quality and COA considerations.
A meaningful COA for this blend must do more than a single-compound COA: it should confirm identity by mass spectrometry for each of the three components, report purity by HPLC, and — critically — report the ratio/proportion of each component, not just a single total mass (without the per-component breakdown you cannot know how much of each you are actually studying). Two component-specific cautions: for Cartalax, because there is no unambiguous peer-reviewed sequence under the brand name, treat the COA's stated amino-acid sequence as the controlling identity; and for the "Thymosin beta-4" component, confirm whether the COA describes the full 43-amino-acid protein or the shorter TB-500 fragment. Endotoxin and sterility should be reported for any injection-model use.

*Research-use note: This monograph is an educational summary of the published research literature and community-reported practice for the Cartalax + BPC-157 + Thymosin beta-4 blend and its individual components. It is for laboratory and research use only. The evidence base is per-component and largely preclinical (Cartalax's is thin and concentrated in one research tradition); there are no controlled trials of the fixed blend; blend dosing is more variable and less studied than single-compound dosing; none of the components is an approved therapy in any major Western jurisdiction; and nothing here is medical advice or a usage recommendation.